Compliance Certificate - Regulation 40(9) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
As per the requirements of Regulation 40(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find herewith the Compliance Certificate dated 22nd October, 2018 issued by M/S. Veenit Pai & Associates, Practicing Company Secretaries, for the half year ended 30th September, 2018. Announcement under Regulation 30 (LODR)-Press Release / Media Release
We are pleased to enclose herewith our Press Release relating to announcement of financial results for the second quarter and first half ending September 30, 2018, which we shall be releasing after sending this letter to you. This is for your information and record. Thanking you, Announcement under Regulation 30 (LODR)-Press Release / Media Release
We are pleased to enclose herewith our Press Release relating to availability of ILUMYATM (tildrakizumab-asmn) in the United States, which we shall be releasing after sending this letter to you. This is for your information and record. Thanking you, Board Meeting Intimation for Notice Of Board Meeting For Consideration And Approval Of Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter And Half Year Ended September 30, 2018 And Intimation Of Dates Of Window Closure For Trading By Designated Persons.
SUN PHARMACEUTICAL INDUSTRIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2018 ,inter alia, to consider and approve This is to inform you that a meeting of the Board of Directors of the Company will be held on Tuesday, November 13, 2018, to consider and approve Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended September 30, 2018.... Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Family Investment Pvt Ltd Shareholding for the Period Ended September 30, 2018
Sun Pharmaceutical Industries Ltd has submitted to BSE the Shareholding Pattern for the Period Ended September 30, 2018. For more details, kindly Click here Statement Of Investor Complaints For The Quarter Ended September 2018
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- ASHOK I BHUTADesignation :- Authorised Signatory Sun Pharma to invest Rs 200 cr more in Assam plant
Assam government on Saturday said medicine firm Sun Pharma will invest an additional Rs 200 crore at its plant in the state to augment operations. As Top buy/sell/hold ideas from D-Street experts
Sun Pharma is a 'Sell' call with a target price of Rs 565 and a stop loss of Rs 600. Compliance Certificate - Regulation 7 (3) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
As per the requirement of Regulation 7 (3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby confirm that all activities in relation to both physical and electronic share transfer facility during the period April 01, 2018 to September 30, 2018 (both days inclusive) are maintained by the Company's Registrar and Share Transfer Agent, viz., Link Intime India Private Limited, which is registered as Registrar &...